{"id":56147,"date":"2026-02-03T16:31:11","date_gmt":"2026-02-03T08:31:11","guid":{"rendered":"https:\/\/flcube.com\/?p=56147"},"modified":"2026-02-03T16:31:12","modified_gmt":"2026-02-03T08:31:12","slug":"imfinzi-gastric-cancer-astrazeneca-secures-chmp-recommendation","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56147","title":{"rendered":"Imfinzi Gastric Cancer: AstraZeneca Secures CHMP Recommendation"},"content":{"rendered":"\n<p><strong>AstraZeneca<\/strong> (AZ, <a href=\"https:\/\/www.google.com\/finance\/quote\/AZN:NYSE\">NASDAQ:\u202fAZN<\/a>) announced that the <strong>Committee for Medicinal Products for Human Use (CHMP)<\/strong> has recommended approval for <strong>Imfinzi (durvalumab)<\/strong> combined with <strong>FLOT chemotherapy<\/strong> for adult patients with <strong>resectable, early-stage and locally advanced (Stages II, III, IVA) gastric and gastroesophageal junction (GEJ) cancers<\/strong>. The perioperative regimen includes neoadjuvant and adjuvant Imfinzi plus chemotherapy followed by Imfinzi monotherapy.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone-amp-clinical-basis\">Regulatory Milestone &amp; Clinical Basis<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>AstraZeneca (NASDAQ:\u202fAZN)<\/td><\/tr><tr><td><strong>Drug<\/strong><\/td><td>Imfinzi (durvalumab)<\/td><\/tr><tr><td><strong>Combination<\/strong><\/td><td>FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, docetaxel)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Resectable gastric\/GEJ cancers (Stages II, III, IVA)<\/td><\/tr><tr><td><strong>Regulatory Body<\/strong><\/td><td>EMA CHMP<\/td><\/tr><tr><td><strong>Recommendation<\/strong><\/td><td>Positive opinion for approval<\/td><\/tr><tr><td><strong>Clinical Basis<\/strong><\/td><td>MATTERHORN Phase\u202f3 trial<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-matterhorn-trial-key-efficacy-data\">MATTERHORN Trial Key Efficacy Data<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Imfinzi + FLOT<\/th><th>Chemotherapy Alone<\/th><th>Result<\/th><\/tr><\/thead><tbody><tr><td><strong>EFS Risk Reduction<\/strong><\/td><td>\u2014<\/td><td>\u2014<\/td><td><strong>29%<\/strong> reduction (P\u202f&lt;\u202f0.05)<\/td><\/tr><tr><td><strong>Median EFS<\/strong><\/td><td>Not reached<\/td><td>32.8 months<\/td><td>Significant improvement<\/td><\/tr><tr><td><strong>OS Risk Reduction<\/strong><\/td><td>\u2014<\/td><td>\u2014<\/td><td><strong>22%<\/strong> reduction (3\u2011year OS: 69% vs 62%)<\/td><\/tr><tr><td><strong>Safety Profile<\/strong><\/td><td>Consistent with known profiles<\/td><td>\u2014<\/td><td>Similar surgery completion rate<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-mechanism-amp-treatment-regimen\">Mechanism &amp; Treatment Regimen<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Perioperative Approach:<\/strong> Neoadjuvant Imfinzi + FLOT \u2192 Surgery \u2192 Adjuvant Imfinzi + FLOT \u2192 Imfinzi monotherapy<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> PD\u2011L1 inhibition enhances anti\u2011tumor immune response, reducing risk of recurrence<\/li>\n\n\n\n<li><strong>Clinical Advantage:<\/strong> First perioperative immunotherapy regimen to show OS benefit in resectable gastric cancer<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-commercial-outlook\">Market Impact &amp; Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>EU Gastric Cancer Market:<\/strong> Estimated <strong>\u20ac1.5\u202fbillion<\/strong> by 2028; resectable stage patients represent <strong>40%<\/strong> of new diagnoses<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> Competes with <strong>CheckMate\u2011649 (Opdivo + chemo)<\/strong> and <strong>KEYNOTE\u2011859 (Keytruda + chemo)<\/strong>; perioperative Imfinzi offers differentiated treatment duration<\/li>\n\n\n\n<li><strong>Strategic Value:<\/strong> Expands Imfinzi\u2019s oncology footprint beyond lung cancer; validates perioperative immuno\u2011oncology approach<\/li>\n\n\n\n<li><strong>Revenue Potential:<\/strong> Analysts project <strong>\u20ac300\u2013500\u202fmillion<\/strong> peak annual EU sales for gastric\/GEJ indication by 2030<\/li>\n\n\n\n<li><strong>Global Development:<\/strong> US FDA submission under evaluation; China NDA planned for 2027<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding regulatory approval timelines, commercial expectations, and revenue projections for Imfinzi. Actual results may differ due to EMA review outcomes, competitive dynamics, and market access negotiations.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>AstraZeneca (AZ, NASDAQ:\u202fAZN) announced that the Committee for Medicinal Products for Human Use (CHMP) has&#8230;<\/p>\n","protected":false},"author":1,"featured_media":56151,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[130,38,871,18],"class_list":["post-56147","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-astrazeneca","tag-market-approval-filings","tag-nasdaq-azn","tag-pd-1-l1"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Imfinzi Gastric Cancer: AstraZeneca Secures CHMP Recommendation - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"AstraZeneca (AZ, NASDAQ:\u202fAZN) announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended approval for Imfinzi (durvalumab) combined with FLOT chemotherapy for adult patients with resectable, early-stage and locally advanced (Stages II, III, IVA) gastric and gastroesophageal junction (GEJ) cancers. The perioperative regimen includes neoadjuvant and adjuvant Imfinzi plus chemotherapy followed by Imfinzi monotherapy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=56147\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Imfinzi Gastric Cancer: AstraZeneca Secures CHMP Recommendation\" \/>\n<meta property=\"og:description\" content=\"AstraZeneca (AZ, NASDAQ:\u202fAZN) announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended approval for Imfinzi (durvalumab) combined with FLOT chemotherapy for adult patients with resectable, early-stage and locally advanced (Stages II, III, IVA) gastric and gastroesophageal junction (GEJ) cancers. The perioperative regimen includes neoadjuvant and adjuvant Imfinzi plus chemotherapy followed by Imfinzi monotherapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=56147\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-03T08:31:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-03T08:31:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0303.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56147#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56147\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Imfinzi Gastric Cancer: AstraZeneca Secures CHMP Recommendation\",\"datePublished\":\"2026-02-03T08:31:11+00:00\",\"dateModified\":\"2026-02-03T08:31:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56147\"},\"wordCount\":307,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56147#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0303.webp\",\"keywords\":[\"AstraZeneca\",\"Market approval filings\",\"NASDAQ: AZN\",\"PD-1\\\/L1\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56147#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56147\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=56147\",\"name\":\"Imfinzi Gastric Cancer: AstraZeneca Secures CHMP Recommendation - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56147#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56147#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0303.webp\",\"datePublished\":\"2026-02-03T08:31:11+00:00\",\"dateModified\":\"2026-02-03T08:31:12+00:00\",\"description\":\"AstraZeneca (AZ, NASDAQ:\u202fAZN) announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended approval for Imfinzi (durvalumab) combined with FLOT chemotherapy for adult patients with resectable, early-stage and locally advanced (Stages II, III, IVA) gastric and gastroesophageal junction (GEJ) cancers. The perioperative regimen includes neoadjuvant and adjuvant Imfinzi plus chemotherapy followed by Imfinzi monotherapy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56147#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56147\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56147#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0303.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0303.webp\",\"width\":1080,\"height\":608,\"caption\":\"Imfinzi Gastric Cancer: AstraZeneca Secures CHMP Recommendation\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56147#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Imfinzi Gastric Cancer: AstraZeneca Secures CHMP Recommendation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Imfinzi Gastric Cancer: AstraZeneca Secures CHMP Recommendation - Insight, China&#039;s Pharmaceutical Industry","description":"AstraZeneca (AZ, NASDAQ:\u202fAZN) announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended approval for Imfinzi (durvalumab) combined with FLOT chemotherapy for adult patients with resectable, early-stage and locally advanced (Stages II, III, IVA) gastric and gastroesophageal junction (GEJ) cancers. The perioperative regimen includes neoadjuvant and adjuvant Imfinzi plus chemotherapy followed by Imfinzi monotherapy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=56147","og_locale":"en_US","og_type":"article","og_title":"Imfinzi Gastric Cancer: AstraZeneca Secures CHMP Recommendation","og_description":"AstraZeneca (AZ, NASDAQ:\u202fAZN) announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended approval for Imfinzi (durvalumab) combined with FLOT chemotherapy for adult patients with resectable, early-stage and locally advanced (Stages II, III, IVA) gastric and gastroesophageal junction (GEJ) cancers. The perioperative regimen includes neoadjuvant and adjuvant Imfinzi plus chemotherapy followed by Imfinzi monotherapy.","og_url":"https:\/\/flcube.com\/?p=56147","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-03T08:31:11+00:00","article_modified_time":"2026-02-03T08:31:12+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0303.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=56147#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=56147"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Imfinzi Gastric Cancer: AstraZeneca Secures CHMP Recommendation","datePublished":"2026-02-03T08:31:11+00:00","dateModified":"2026-02-03T08:31:12+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=56147"},"wordCount":307,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=56147#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0303.webp","keywords":["AstraZeneca","Market approval filings","NASDAQ: AZN","PD-1\/L1"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=56147#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=56147","url":"https:\/\/flcube.com\/?p=56147","name":"Imfinzi Gastric Cancer: AstraZeneca Secures CHMP Recommendation - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=56147#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=56147#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0303.webp","datePublished":"2026-02-03T08:31:11+00:00","dateModified":"2026-02-03T08:31:12+00:00","description":"AstraZeneca (AZ, NASDAQ:\u202fAZN) announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended approval for Imfinzi (durvalumab) combined with FLOT chemotherapy for adult patients with resectable, early-stage and locally advanced (Stages II, III, IVA) gastric and gastroesophageal junction (GEJ) cancers. The perioperative regimen includes neoadjuvant and adjuvant Imfinzi plus chemotherapy followed by Imfinzi monotherapy.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=56147#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=56147"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=56147#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0303.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0303.webp","width":1080,"height":608,"caption":"Imfinzi Gastric Cancer: AstraZeneca Secures CHMP Recommendation"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=56147#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Imfinzi Gastric Cancer: AstraZeneca Secures CHMP Recommendation"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0303.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56147","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56147"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56147\/revisions"}],"predecessor-version":[{"id":56152,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56147\/revisions\/56152"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/56151"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56147"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56147"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56147"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}